IP Group

Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Inosi Therapeutics is a biotechnology company focused on developing innovative therapies to treat fibrosis, a condition characterized by tissue damage and scarring that can result in the loss of organ function. The company is pioneering a therapeutic approach that utilizes IRAP inhibitors, which can be tested independently or in conjunction with existing standard treatments. This unique mechanism of action aims to enhance the treatment of organ damage related to diabetes-induced kidney disease and cardiovascular disease. By addressing the underlying causes of fibrosis, Inosi Therapeutics aims to provide healthcare providers with effective solutions for managing chronic diseases associated with significant tissue damage.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Oxular is a clinical-stage company developing innovative retinal therapeutics. It focuses on transforming the treatment of retinal diseases by offering tissue-specific drug delivery solutions to address unmet patient needs, such as age-related macular degeneration and diabetic macular edema.

Centessa Pharmaceuticals is a biopharmaceutical company that focuses on advancing validated drug programs through an asset-centric R&D model. Each program is developed by dedicated subsidiaries, supported by centralized infrastructure and expert management.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Founded in 2017, Kira Biotech is an Australian biotechnology company dedicated to developing novel immunomodulatory compounds. Its lead candidate, KB312, is a first-in-class monoclonal antibody targeting activated immune cells to induce immune tolerance and treat immune system disorders such as rheumatoid arthritis and systemic lupus erythematosus.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Lorem Therapeutics is focusing on development early stage therapeutics in the phase between initial drug discovery and when a treatment begins review by the FDA for status as an Investigational New Drug. The company will use the funding “to accelerate and enhance our drug discovery efforts around critical cancer indications,” Slusher said in a statement.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

OxSyBio Ltd. is a biotechnology company based in London, United Kingdom, specializing in the development of advanced 3D printing techniques for creating tissue-like and functional tissues intended for medical research and clinical applications. Founded in 2014, the company focuses on innovative methods that utilize three-dimensional networks of lipid monolayer aqueous droplets, which can conduct electrical signals along designated pathways and self-fold into intricate structures. These engineered tissues aim to facilitate organ repair or replacement, supporting precision medicine initiatives. The technology builds upon pioneering research from Professor Hagan Bayley's group at the University of Oxford, emphasizing the integration of chemical and synthetic biology in the field of regenerative medicine.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

Zilico develops medical diagnostic devices using electrical impedance spectroscopy technology. Its primary product, ZedScan, enhances cervical cancer diagnosis by providing real-time, objective assessments alongside colposcopy.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Cambridge Innovation Capital is a Cambridge-based venture capital firm that specializes in early-stage and growth investments in life sciences and technology. It focuses on companies affiliated with the University of Cambridge or the Cambridge Cluster and seeks to back innovations in therapeutics, medtech and diagnostics, digital health, genomics and proteomics, artificial intelligence, the Internet of Things, quantum technologies, and autonomous systems. The organization provides long-term equity capital to help portfolio companies bridge development stages and scale, with a strong emphasis on opportunities arising from the Cambridge ecosystem. Since its founding in 2013, Cambridge Innovation Capital has established itself as a leading investor within that community, leveraging close ties to academia to access high-potential deep-tech opportunities.

Avacta Group specializes in life science technologies and reagents for applications ranging from drug discovery to diagnostics. It operates through Analytical and Animal Health segments, offering tools and contract services for protein analysis in biopharmaceutical development and veterinary diagnostics.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.

OxSyBio Ltd. is a biotechnology company based in London, United Kingdom, specializing in the development of advanced 3D printing techniques for creating tissue-like and functional tissues intended for medical research and clinical applications. Founded in 2014, the company focuses on innovative methods that utilize three-dimensional networks of lipid monolayer aqueous droplets, which can conduct electrical signals along designated pathways and self-fold into intricate structures. These engineered tissues aim to facilitate organ repair or replacement, supporting precision medicine initiatives. The technology builds upon pioneering research from Professor Hagan Bayley's group at the University of Oxford, emphasizing the integration of chemical and synthetic biology in the field of regenerative medicine.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, focusing on the ubiquitin and ubiquitin-like signaling systems. The company provides protein degradation-focused drug discovery services and designs novel deubiquitylase (DUB) enzyme inhibitors as potential therapeutics for addressing unmet medical needs. Ubiquigent collaborates with both academic and pharmaceutical researchers, supporting fundamental scientific discovery and the exploration of innovative drug candidates targeting DUBs. Its hybrid business model emphasizes the generation of intellectual property while maintaining an internal pipeline of drug discovery programs aimed at optimizing compounds for critical therapeutic areas.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.

Iksuda Therapeutics is a biotechnology company focused on developing next-generation biotherapeutics, specifically antibody-drug conjugates designed to treat challenging cancers, including those resistant to current therapies.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Activiomics Ltd. is a biotechnology company specializing in biomarker technology and phosphoproteomics solutions aimed at enhancing biomarker discovery and drug candidate profiling. The company has developed a patented mass spectrometry-based technology that facilitates the global quantitative analysis of phosphorylation sites, which are critical mediators of cellular processes. This technology, known as TIQUAS (Targeted In-depth QUAntification of cell Signalling), allows for the quantification of thousands of phosphorylation events from tissue samples. By identifying and quantifying proteins and phosphoproteins that correlate with disease progression and drug administration, Activiomics aims to transform the development of diagnostics and therapeutic strategies.

Iksuda Therapeutics is a biotechnology company focused on developing next-generation biotherapeutics, specifically antibody-drug conjugates designed to treat challenging cancers, including those resistant to current therapies.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

TheraGenetics was spun out of King's College London in April 2006. Their technology is based upon pharmacogenetics; the study of genetic factors involved in influencing an individual's response to drug treatments. The strong foundation of TheraGenetics stems from the founding team's long commitment to pharmacogenetics that has situated us at the cutting edge of personalised medicine. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the commercial world by developing the first pharmacogenetic test for response prediction in psychiatry. In 2005, this test which focuses on the schizophrenia treatment clozapine, was successfully licensed by King's College London to a major UK laboratory who have successfully brought the test to market in 2006. Based on this achievement and the overwhelming enthusiasm for personalised medicine solutions, King's College London, the academic founders and the London based venture firm IPGroup PLC launched TheraGenetics in April 2006. TheraGenetics unique knowledge and experience in CNS disorders extends from the bench to the bedside. The ultimate clinical utility has been a priority consideration at all stages of their test development; their clinical team knows what is required at the patient care interface and they develop tests accordingly. The TheraGenetic's team has a threshold of knowledge and experience spanning the whole test development process that is now allowing us to rapidly advance their work in the field of pharmacogenetic response prediction.

Cerogenix is a drug discovery and diagnostics.